Early detection: The power and the promise of DNA methylation markers

By Peter W. Laird. Nature Reviews. Cancer, 2003

1,280 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/1fd7be95b333ad74f105a03de7d6ae741fca4c4d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Cancer epigenetics. (2005, background): “Disease detection is useful not only for the early detection of undiagnosed malignancies but also for the monitoring of recurrent disease as a measure of therapeutic efficacy (60).”
An integrated resource for genome-wide identification and analysis of human tissue-specific differentially methylated regions (tDMRs). (2008, background): “Its importance is further underlined by observations that various complex diseases such as cancer are associated with perturbed DNA methylation profiles ( Laird 2003 ).”
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. (2010, background): “CpG island hypermethylation events have also been shown to serve as biomarkers in human cancers, for early detection in blood and other bodily fluids, for prognosis or prediction of response to therapy, and to monitor cancer recurrence (Laird, 2003).”
Principles and challenges of genome-wide DNA methylation analysis (2010, background): “Measurements can be made either of the pattern of methylated target sequences along individual DNA molecules or as an average methylation level at a single genomic locus across many DNA molecule”
Epigenetics in human disease and prospects for epigenetic therapy (2004, background): “( page 469 ) and Bell ( page 453 )) and epigenetic marker”
Cancer epigenomics: DNA methylomes and histone-modification maps (2007, methodology): “For the various cancers for which DNA-methylation profiles are available, CpG-island hypermethylation has been used as a tool to detect cancer cells in all types of biological fluid and biops”
Cancer epigenetics reaches mainstream oncology (2011, background): “The recent advances in technologies that couple bisulphite modification of DNA with PC”
DNA methylation and cancer. (2004, methodology): “imprinting, developmental abnormalities, mental health, and X-inactivation.(5,6)”
Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? (2006, background): “The chromatin changes that are involved, such as abnormal promoter methylation, might also be assayed in DNA from various sources as a promising molecular-marker strategy to aid cancer risk assessment, early detection and prognosi”
DNA methylation age of human tissues and cell types (2013, background): “particular, cancer tissues were excluded from this first large data set since it is well known that cancer has a profound effect on DNA methylation levels [6,7,24-26].”
Analysis of repetitive element DNA methylation by MethyLight (2005, background): “CpG dinucleotides are underrepresented in the human genome by a factor of about 5, due to the spontaneous deamination of 5-methylcytosine residues, resulting in C-to-T transition mutations at CpG dinucleotides ( 2 ).”
MeInfoText: associated gene methylation and cancer information from text mining (2008, background): “Currently, many studies have corroborated the DNA methylation profile of a cell type which may serve as a biomarker with a diagnostic and prognostic value [8].”